Immunotherapy and lung cancer: current developments and novel targeted therapies

被引：72

作者：

Domingues, Duarte ^{[1
,2
]}

Turner, Alice ^{[3
]}

Silva, Maria Dilia ^{[2
]}

Marques, Dania Sofia ^{[1
]}

Mellidez, Juan Carlos ^{[2
]}

Wannesson, Luciano ^{[4
]}

Mountzios, Giannis ^{[5
]}

de Mello, Ramon Andrade ^{[1
,6
]}

机构：

[1] Portuguese Oncol Inst IPO PORTO, Dept Med Oncol, P-4200072 Oporto, Portugal

[2] Hosp Infante Dom Pedro, Dept Med Oncol, Aveiro, Portugal

[3] Univ Otago, Sch Med, Christchurch 8011, New Zealand

[4] Oncol Inst Southern Switzerland IOSI, CH-6500 Bellinzona, Switzerland

[5] Univ Athens, Sch Med, Dept Med Oncol, GR-11527 Athens, Greece

[6] Univ Algarve, Sch Med, Dept Biomed Sci & Med, P-8005139 Faro, Portugal

来源：

IMMUNOTHERAPY | 2014年 / 6卷 / 11期

关键词：

checkpoint inhibitors; immunotherapies; lung cancer; nivolumab; tremelimumab; tumor vaccines; BLP25 LIPOSOME VACCINE; PHASE-II; DOUBLE-BLIND; ORAL TALACTOFERRIN; 1ST-LINE TREATMENT; RADIATION-THERAPY; STAGE-IIIB; T-CELLS; TRIAL; CHEMOTHERAPY;

D O I：

10.2217/imt.14.82

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

071005 [微生物学]; 100108 [医学免疫学];

摘要：

Non-small-cell lung cancer (NSCLC) is a highly prevalent and aggressive disease. In the metastatic setting, major advances include the incorporation of immunotherapy and targeted therapies into the clinician's therapeutic armamentarium. Standard chemotherapeutic regimens have long been reported to interfere with the immune response to the tumor; conversely, antitumor immunity may add to the effects of those therapies. The aim of immunotherapy is to specifically enhance the immune response directed to the tumor. Recently, many trials addressed the role of such therapies for metastatic NSCLC treatment: ipilimumab, tremelimumab, nivolumab and lambrolizumab are immunotherapeutic agents of main interest in this field. In addition, anti-tumor vaccines, such as MAGE-A3, Tecetomide, TG4010, CIMAvax, ganglioside vaccines, tumor cell vaccines and dendritic cell vaccines, emerged as potent inducers of immune response against the tumor. The current work aims to address the most recent developments regarding these innovative immunotherapies and their implementation in the treatment of metastatic NSCLC.

引用

页码：1221 / 1235

页数：15

共 69 条

[1]

Tumor-Specific Cytotoxic T Cells Are Crucial for Efficacy of Immunomodulatory Antibodies in Patients with Lung Cancer [J].

Aerts, Joachim G. ;

Hegmans, Joost P. .

CANCER RESEARCH, 2013, 73 (08) :2381-2388

[2]

A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients [J].

Alfonso, Sailyn ;

Valdes-Zayas, Anet ;

Santiesteban, Eduardo R. ;

Flores, Yoanna I. ;

Areces, Fernando ;

Hernandez, Maurenis ;

Viada, Carmen E. ;

Mendoza, Ivis C. ;

Guerra, Pedro P. ;

Garcia, Elena ;

Ortiz, Ramon A. ;

de la Torre, Ana V. ;

Cepeda, Meylan ;

Perez, Kirenia ;

Chong, Eric ;

Maria Hernandez, Ana ;

Toledo, Darien ;

Gonzalez, Zuyen ;

Mazorra, Zaima ;

Crombet, Tania ;

Perez, Rolando ;

Maria Vazquez, Ana ;

Macias, Amparo E. .

CLINICAL CANCER RESEARCH, 2014, 20 (14) :3660-3671

[3]

Frequent T cell responses against immunogenic targets in lung cancer patients for targeted immunotherapy [J].

Babiak, Anna ;

Steinhauser, Max ;

Goetz, Marlies ;

Herbst, Cornelia ;

Doehner, Hartmut ;

Greiner, Jochen .

ONCOLOGY REPORTS, 2014, 31 (01) :384-390

[4]

Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].

Brahmer, Julie R. ;

Tykodi, Scott S. ;

Chow, Laura Q. M. ;

Hwu, Wen-Jen ;

Topalian, Suzanne L. ;

Hwu, Patrick ;

Drake, Charles G. ;

Camacho, Luis H. ;

Kauh, John ;

Odunsi, Kunle ;

Pitot, Henry C. ;

Hamid, Omid ;

Bhatia, Shailender ;

Martins, Renato ;

Eaton, Keith ;

Chen, Shuming ;

Salay, Theresa M. ;

Alaparthy, Suresh ;

Grosso, Joseph F. ;

Korman, Alan J. ;

Parker, Susan M. ;

Agrawal, Shruti ;

Goldberg, Stacie M. ;

Pardoll, Drew M. ;

Gupta, Ashok ;

Wigginton, Jon M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465

[5]

Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].

Brahmer, Julie R. ;

Drake, Charles G. ;

Wollner, Ira ;

Powderly, John D. ;

Picus, Joel ;

Sharfman, William H. ;

Stankevich, Elizabeth ;

Pons, Alice ;

Salay, Theresa M. ;

McMiller, Tracee L. ;

Gilson, Marta M. ;

Wang, Changyu ;

Selby, Mark ;

Taube, Janis M. ;

Anders, Robert ;

Chen, Lieping ;

Korman, Alan J. ;

Pardoll, Drew M. ;

Lowy, Israel ;

Topalian, Suzanne L. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175

[6]

Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer [J].

Butts, C ;

Murray, N ;

Maksymiuk, A ;

Goss, G ;

Marshall, E ;

Soulières, D ;

Cormier, Y ;

Ellis, P ;

Price, A ;

Sawhney, R ;

Davis, M ;

Mansi, J ;

Smith, C ;

Vergidis, D ;

Ellis, P ;

MacNeil, M ;

Palmer, M .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (27) :6674-6681

[7]

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial [J].

Butts, Charles ;

Socinski, Mark A. ;

Mitchell, Paul L. ;

Thatcher, Nick ;

Havel, Libor ;

Krzakowski, Maciej ;

Nawrocki, Sergiusz ;

Ciuleanu, Tudor-Eliade ;

Bosquee, Lionel ;

Manuel Trigo, Jose ;

Spira, Alexander ;

Tremblay, Lise ;

Nyman, Jan ;

Ramlau, Rodryg ;

Wickart-Johansson, Gun ;

Ellis, Peter ;

Gladkov, Oleg ;

Pereira, Jose Rodrigues ;

Eberhardt, Wilfried Ernst Erich ;

Helwig, Christoph ;

Schroeder, Andreas ;

Shepherd, Frances A. .

LANCET ONCOLOGY, 2014, 15 (01) :59-68

[8]

Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial [J].

Butts, Charles ;

Maksymiuk, Andrew ;

Goss, Glenwood ;

Soulieres, Denis ;

Marshall, Ernie ;

Cormier, Yvon ;

Ellis, Peter M. ;

Price, Allan ;

Sawhney, Ravinder ;

Beier, Frank ;

Falk, Martin ;

Murray, Nevin .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2011, 137 (09) :1337-1342

[9]

CHAHINIAN AP, 1982, CANCER TREAT REP, V66, P1291

[10]

Unique pulmonary antigen presentation may call for an alternative approach toward lung cancer immunotherapy [J].

Chang, Stephanie ;

Lin, Xue ;

Higashikubo, Ryuji ;

Toth, Kelsey ;

Gelman, Andrew E. ;

Kreisel, Daniel ;

Krupnick, Alexander S. .

ONCOIMMUNOLOGY, 2013, 2 (03)

← 1 2 3 4 5 6 7 →